Goldman B D
NYU Downtown Hospital, New York, NY 10038, USA.
Arch Dermatol. 2000 Sep;136(9):1158-61. doi: 10.1001/archderm.136.9.1158.
Serologic tests for antibodies to herpes simplex virus (HSV) have traditionally played a limited role in the treatment of patients with genital herpes. The epidemiological gold standard has been the Western blot analysis, which is only available in a few research centers and is expensive. The gold standard of diagnosis for HSV infection has been viral culture. Diagnosis by viral culture has severely underestimated the number of individuals infected. The majority of patients who are seropositive for herpes simplex virus type 2 (HSV-2) by Western blot analysis are unaware of their symptoms (unrecognized infection) or have subclinical infection. These patients are unlikely to present for culture. Enzyme-linked immunosorbent assay (ELISA) for the serologic diagnosis of herpes has been available for many years but suffers from poor sensitivity and specificity. Reliable, convenient serologic tests for antibodies that distinguish between prior infection with HSV-1 and HSV-2 have recently become commercially available.
传统上,单纯疱疹病毒(HSV)抗体的血清学检测在生殖器疱疹患者的治疗中作用有限。流行病学的金标准是蛋白质印迹分析,该方法仅在少数研究中心可用且成本高昂。HSV感染的诊断金标准一直是病毒培养。通过病毒培养进行的诊断严重低估了感染个体的数量。通过蛋白质印迹分析检测出单纯疱疹病毒2型(HSV-2)血清阳性的大多数患者没有意识到自己的症状(未被识别的感染)或存在亚临床感染。这些患者不太可能去进行病毒培养。用于疱疹血清学诊断的酶联免疫吸附测定(ELISA)已经存在多年,但灵敏度和特异性较差。最近,用于区分既往HSV-1和HSV-2感染的可靠、便捷的抗体血清学检测已上市。